Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Keratosis, Actinic 4

Interventions

3-ingenyl angelate 39Imiquimod 22Aminolevulinic Acid 22Photochemotherapy 16methyl 5-aminolevulinate 12Fluorouracil 11Diclofenac 11Gels 10Cryotherapy 6Solutions 5BF-200 ALA 5tirbanibulin 4Radiotherapy 4Prilocaine 4Lidocaine 4LEO 43204 4Petrolatum 3Ointments 3Cryosurgery 3calcipotriene 2SR-T100 2Niacinamide 2Blue Light 21-phenyl-3,3-dimethyltriazene 2tazarotene 1potassium dobesilate 1perillyl alcohol 1endonuclease V, phage T4 1dexpanthenol 1cetyl alcohol, propylene glycol, sodium lauryl sulfate non-lipid cleansing lotion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Keratosis, Actinic × LEO 43204 × Clear all
NCT02305888 2025-03-10

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

LEO Pharma

Phase 2 Completed
189 enrolled 9 charts
Dermatologic

Keratosis, Actinic

NCT02100813 2025-03-06

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

LEO Pharma

Phase 1/2 Completed
220 enrolled 19 charts
Dermatologic

Keratosis, Actinic

NCT02120456 2025-03-06

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

LEO Pharma

Phase 1/2 Completed
224 enrolled 21 charts
Dermatologic

Keratosis, Actinic

NCT02650505 2025-02-24

A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel

LEO Pharma

Phase 1 Completed
233 enrolled
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡